Compare CCOI & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCOI | ATAI |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2002 | 2025 |
| Metric | CCOI | ATAI |
|---|---|---|
| Price | $17.76 | $3.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $29.11 | $15.88 |
| AVG Volume (30 Days) | 1.4M | ★ 6.4M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | ★ 11.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $975,766,000.00 | $4,089,000.00 |
| Revenue This Year | $11.76 | N/A |
| Revenue Next Year | $6.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $14.82 | $1.89 |
| 52 Week High | $54.37 | $6.73 |
| Indicator | CCOI | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 46.18 |
| Support Level | $16.10 | $3.89 |
| Resistance Level | $25.41 | $4.13 |
| Average True Range (ATR) | 1.47 | 0.23 |
| MACD | -0.19 | -0.04 |
| Stochastic Oscillator | 31.24 | 11.61 |
Cogent carries over one-fifth of the world's internet traffic on its network, providing high-capacity services to businesses. Cogent's corporate customers are in high-rise office buildings, where the firm provides two types of connections: dedicated internet access, which connects them to the internet, and virtual private networking, which offers an internal network for employees in different locations. Cogent's corporate customers are exclusively in North America and account for nearly half of the firm's revenue. Cogent's netcentric customers include internet service providers and content providers, to which Cogent provides internet transit. They hand traffic to Cogent in data centers and rely on Cogent to deliver it. About half of netcentric revenue is from outside the US.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.